MAPT and Cognitive impairment: Further research on the use of combinations of biomarkers, for example Aβ1–42 levels in conjunction with other markers (e.g., total Aβ, Aβ1–40, tau, phosphorylated tau), will be necessary in order to develop CSF biochemical measurements permitting reliable diagnosis of AD versus other non-AD cognitive impairments.